Chemotherapy Induced Peripheral Neuropathy

1
CHEMOTHAREPY INDUCED PERIPHERAL NEUROPATHY
Market Insights, Epidemiology and Market Forecast
- 2027
Delveinsight 2018 All rights reserved
2
INTRODUCTION
With the exception of paclitaxel and oxaliplatin,
which causes an acute neuropathy that emerges
either during or shortly after infusion, the
onset of CIPN is usually delayed and appears to
depend on the total cumulative dose.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
is a frequent, dose-dependent complication of
anticancer drugs, including platinums, taxanes,
epothilones, vinca alkaloids, and newer agents,
such as bortezomib.
It not only leads to dose reduction or
discontinuation of treatment but also decreases
the quality of life of cancer survivors.
Delveinsight 2018 All rights reserved
3
Prevalence of CIPN FROM 2016 - 2027
Delveinsight 2018 All rights reserved
4
MARKET SIZE
The market size of currently prescribed offlabel
therapies for the treatment of CIPN is expected
to initially experience steady growth, and will
further decrease owing to the launch of upcoming
therapies in forecast period 2018-2027
Expected launch of SP-04 (Solasia), Tetrodotoxin
(WEX Pharmaceuticals), and E-52862 (Esteve)
during the forecast period (2018-2027) may create
a positive impact on the CIPN market
02
04
01
03
05
The assessment of CIPN is not standardized and
thus acts as a restraint in the
therapeutic market of this indication.
Owing to the launch of promising therapies,
market size is expected to increase in the G8,
during the forecast period (2018-2027)
Companies are focused on the development of
targeted therapies for the treatment of CIPN,
which are expected to create an evident impact on
the market revenue in coming years
Delveinsight 2018 All rights reserved
5
EMERGING DRUGS AND COMPANIES
Chroma Dex
NIAGEN
DARA Biosciences
Medicinova
MN - 166
KRN 5500
3
2
4
Apollo Endosurgery
WEX Pharmaceuticals
DRUGS
1
5
Tetrodotoxin
Lpathomab
Delveinsight 2018 All rights reserved
6
About delveinsight
about
mISSION
vision
01
02
03
DelveInsight, market research and consulting
firm, provides end to end comprehensive solutions
to the Life Science Industry We help our
customers in best decision making through our
expertise in research analysis and comes out
with unmatched data forecasts
insight across the value chain to help
organizations make important business decisions
through the use and analysis of actionable market
intelligence
To be the most trusted marketing research firm
business consulting firm world wide. To be a
renowned and premier data driven solution
providers among Pharma Biotech companies
Delveinsight 2018 All rights reserved
7
Services Offered By Delveinsight
Delveinsight 2018 All rights reserved
8
REPORT PRICE
18750
9500
12500
6250
Delveinsight 2018 All rights reserved
9
CONTACT US
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight
twitter/delveInsight
LinkedIn/delveInsight
Delveinsight 2018 All rights reserved
10
complete INFORMATION
For Complete Information please Click below
Click here
Or Write us at info_at_delveinsight.com
Delveinsight 2018 All rights reserved
11
Delveinsight 2018 All rights reserved